Mineralys Therapeutics (MLYS) EBITDA (2022 - 2026)

Mineralys Therapeutics has disclosed EBITDA across 5 years of filings, most recently posting -$45.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$45.3 million, down 2.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$171.5 million (up 14.88% YoY), and the FY2025 annual result was -$170.6 million, up 11.33% from the prior year.
• EBITDA came in at -$45.3 million for Q1 2026 at Mineralys Therapeutics, down from -$38.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.5 million in Q2 2022 to a low of -$60.1 million in Q3 2024.
• The 5-year median for EBITDA is -$35.4 million (2024), against an average of -$30.9 million.
• Across the five-year window, EBITDA sank 253.94% in 2023 and surged 31.57% in 2025, its largest moves.
• Mineralys Therapeutics' EBITDA stood at -$10.0 million in 2022, then sank by 176.89% to -$27.7 million in 2023, then plunged by 86.81% to -$51.8 million in 2024, then grew by 26.05% to -$38.3 million in 2025, then slipped by 18.44% to -$45.3 million in 2026.
• The last three EBITDA figures came in at -$45.3 million (Q1 2026), -$38.3 million (Q4 2025), and -$41.1 million (Q3 2025), per Business Quant data.